GNNSF

PINK Genscript Biotech Corporation

Oct 26, 2026 · 9:29 AM ET EOD Market Closed

$4.25 ↑ +0.08 (+1.80%) Trading Up from the previous close of $4.18, and at the day’s high of $4.25

YTD change: +45.05%
vs 20-day SMA: -16.01%
vs 200-day SMA: N/A

Price ranges

Previous day

$4.25 $4.25

open $4.25 close $4.25

+$0.00 (+0.00%)

Today

$4.25 $4.25

$4.25

Past week

$4.05 $5.50

from $5.20 now $4.25

-$0.95 (-18.27%)

Past month

$4.00 $6.55

from $4.65 now $4.25

-$0.40 (-8.60%)

This year

$1.30 $6.55

from $2.93 now $4.25

+$1.32 (+45.05%)

Price & Performance

+2.70 (+174.19%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral

The stock is 35.1% away from all-time highs of $6.55
GNNSF is up 45% since the beginning of the year
GNNSF is up 45% over the past 12 months
GNNSF is down 9% over the past 1 month
1% of all GNNSF investors are betting against GNNSF

GNNSF reads neutral: the 12-month move is +133.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable N/A

EPS N/A

Earnings momentum N/A Quarterly EPS growth

Quarterly change N/A

Valuation

P/E ratio N/A

Beta 1.68

Balance sheet & scale

IncomeN/A

Revenue$845.0M

Cash$831.3M

Debt$344.8K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $9.6B

Genscript Biotech Corp. operates as a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Life-science Services and Products, Biologics Development Services, and Industrial Synthetic Biology Products. The Life-science Services and Products segment provides research services and products used for life-science research and application. The Biologics Development Services segment focuses on services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and CGT products with an integrated platform. The Industrial Synthetic Biology Products segment comprises of industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Hong Kong.

Competitor comparison

Ticker	Company	Price	Change
ARGNF	argenx SE	$790.15	-15.58%
GLXY	Galaxy Digital Inc. Class A	$14.68	-3.99%
PVLA	Palvella Therapeutics, Inc.	$125.10	-1.02%
EPRX	Eupraxia Pharmaceuticals, Inc.	$6.87	-9.49%
CLRPF	Clarity Pharmaceuticals Ltd.	$1.12	-10.80%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.